Search

Displaying results 1961 - 1970 of 7498 in total
  1. Drug

    Crotalus atrox antivenin

    go.drugbank.com/drugs/DB13892
    Approved

    The final purified antivenin product is produced by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques. … It is intravenously (IV) administered to prevent/limit systemic toxicity [FDA label].

  2. Drug

    Auranofin

    go.drugbank.com/drugs/DB00995
    ApprovedInvestigational

    It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA.

    Synonyms: 2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold
  3. Drug

    Ecabet

    go.drugbank.com/drugs/DB05265
    Investigational

    Ecabet is a prescription eye drop for the treatment of dry eye syndrome. … Ecabet represents a new class of molecules that increases the quantity and quality of mucin produced by conjunctival goblet cells and corneal epithelia.

  4. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular

  5. Drug

    Hydrocortamate

    go.drugbank.com/drugs/DB00769
    Approved

    Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic … Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses.

  6. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    a procedure by increasing platelet counts to the optimal level ≥50,000 per microliter. … [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure.

  7. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results

  8. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64040,L64041] It is taken by mouth once daily. … not candidates for multiagent systemic therapy.

  9. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … PEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein.

  10. Drug

    Hyoscyamine

    go.drugbank.com/drugs/DB00424
    ApprovedInvestigational

    [L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] … [A228423] Research into the action of hyoscyamine in published literature dates back to 1826.

    Mixtures: UR N-C Urinary Antiseptic